ETF Holdings Breakdown of VERA

VERA institutional holdings

The following institutional investment holdings of VERA have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	29,972	USD 931,530 4.4%	31.08
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	20,313 -0.3%	USD 631,328 4.1%	31.08
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	41,058 0.3%	USD 1,276,083 4.7%	31.08
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	41,058 0.3%	USD 1,276,083 4.7%	31.08
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	293	USD 9,106 4.4%	31.08
Total =		132,694	USD 4,124,130

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with VERA

Deutsche Bank AG Purchases 82,483 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Deutsche Bank AG raised its position in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 10.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 892,859 shares of the company’s stock after buying an additional 82,483 shares during the quarter. Deutsche […] - 2025-08-14 04:59:05

Brokerages Set Vera Therapeutics, Inc. (NASDAQ:VERA) Price Target at $63.00

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on […] - 2025-08-12 02:30:47

Patrick G. Enright Acquires 209,393 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) Director Patrick G. Enright purchased 209,393 shares of the business’s stock in a transaction dated Monday, June 23rd. The stock was purchased at an average price of $20.87 per share, for a total transaction of $4,370,031.91. Following the completion of the acquisition, the director now owns 3,569,522 […] - 2025-06-27 05:06:47

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Insider Buying Activity

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) shares gapped up prior to trading on Thursday after an insider bought additional shares in the company. The stock had previously closed at $23.31, but opened at $25.06. Vera Therapeutics shares last traded at $23.00, with a volume of 369,080 shares. Specifically, Director Patrick G. Enright bought […] - 2025-06-27 02:17:07

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $65.00 Average PT from Analysts

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. […] - 2025-06-23 02:36:56

Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Update

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 8,950,000 shares, an increase of 26.6% from the May 15th total of 7,070,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio […] - 2025-06-20 02:56:59

Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Rhumbline Advisers

Rhumbline Advisers lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 7.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,189 shares of the company’s stock after acquiring an additional 4,600 shares during the period. Rhumbline Advisers’ holdings […] - 2025-06-19 04:10:49

Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Bank of America Corp DE lessened its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 77.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 30,244 shares of the company’s stock after selling 106,673 shares during the period. Bank of America Corp DE’s holdings in Vera Therapeutics were worth $1,279,000 […] - 2025-06-06 04:36:59

Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $85.00 at HC Wainwright

Vera Therapeutics (NASDAQ:VERA – Get Free Report) had its price objective raised by analysts at HC Wainwright from $75.00 to $85.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 174.99% from the company’s previous close. […] - 2025-06-04 03:14:43

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up on Analyst Upgrade

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report)’s share price gapped up before the market opened on Monday after Scotiabank raised their price target on the stock from $55.00 to $65.00. The stock had previously closed at $18.95, but opened at $31.74. Scotiabank currently has a sector outperform rating on the stock. Vera Therapeutics shares […] - 2025-06-04 02:01:03

Vera Therapeutics, Inc. (NASDAQ:VERA) Stake Lessened by Two Sigma Investments LP

Two Sigma Investments LP cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 14.6% during the 4th quarter, HoldingsChannel reports. The fund owned 41,451 shares of the company’s stock after selling 7,102 shares during the period. Two Sigma Investments LP’s holdings in Vera Therapeutics were worth $1,753,000 as of its most recent […] - 2025-06-03 04:38:55

Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Scotiabank Analyst Says

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price objective increased by Scotiabank from $55.00 to $65.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a sector outperform rating on the stock. Other equities analysts also recently issued reports about the company. Wolfe Research initiated coverage on Vera Therapeutics […] - 2025-06-03 02:52:45

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) has earned a consensus rating of “Buy” from the ten ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. […] - 2025-05-26 02:20:49

D. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

D. E. Shaw & Co. Inc. trimmed its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 42.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,476 shares of the company’s stock after selling 55,990 shares during the quarter. D. E. […] - 2025-05-19 05:12:57

HC Wainwright Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)

Investment analysts at HC Wainwright assumed coverage on shares of Vera Therapeutics (NASDAQ:VERA – Get Free Report) in a report issued on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $75.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 240.75% from the stock’s previous close. […] - 2025-05-07 02:22:48

Raymond James Financial Inc. Purchases Shares of 69,724 Vera Therapeutics, Inc. (NASDAQ:VERA)

Raymond James Financial Inc. acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 69,724 shares of the company’s stock, valued at approximately $2,948,000. Raymond James Financial Inc. owned approximately 0.11% of Vera Therapeutics […] - 2025-04-29 05:05:11

Renaissance Technologies LLC Takes $1.51 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Renaissance Technologies LLC purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 35,700 shares of the company’s stock, valued at approximately $1,510,000. Several other institutional investors and hedge funds […] - 2025-04-28 05:46:51

Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLC

Barclays PLC grew its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 16.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 99,148 shares of the company’s stock after buying an additional 13,753 shares during the period. Barclays PLC’s holdings in Vera Therapeutics were worth $4,192,000 as of its […] - 2025-04-28 04:59:04

Legal & General Group Plc Acquires 4,227 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Legal & General Group Plc boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 9.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,809 shares of the company’s stock after purchasing an additional 4,227 shares during the period. […] - 2025-04-25 05:13:08

Investors Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA)

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 8,008 call options on the stock. This is an increase of approximately 2,661% compared to the average volume of 290 call options. Analyst Upgrades and Downgrades A number of brokerages have recently weighed in on […] - 2025-04-25 02:12:48

Geode Capital Management LLC Has $48.79 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Geode Capital Management LLC boosted its position in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 14.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,153,325 shares of the company’s stock after purchasing an additional 148,660 shares during the period. Geode Capital Management LLC owned about 1.82% […] - 2025-04-15 05:00:50

Fmr LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Fmr LLC lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 9.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,053,126 shares of the company’s stock after buying an additional 267,842 shares during the period. Fmr LLC owned approximately 4.82% […] - 2025-04-14 05:23:01

Vanguard Group Inc. Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 14.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,949,564 shares of the company’s stock after purchasing an additional 369,387 shares during the quarter. Vanguard Group Inc.’s holdings in Vera Therapeutics were worth $124,737,000 as of […] - 2025-04-09 04:42:53

American Century Companies Inc. Has $18.14 Million Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

American Century Companies Inc. grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 11.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 428,940 shares of the company’s stock after acquiring an additional 42,526 shares during […] - 2025-04-01 06:10:47

Relative Strength Alert For Vera Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-03-25 14:24:58

Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 515.0% in the fourth quarter, HoldingsChannel reports. The firm owned 235,267 shares of the company’s stock after buying an additional 197,014 shares during the period. Victory Capital Management Inc.’s holdings in Vera Therapeutics were worth $9,949,000 as […] - 2025-03-14 05:50:47

Vera Therapeutics (NASDAQ:VERA) Given New $71.00 Price Target at JPMorgan Chase & Co.

Vera Therapeutics (NASDAQ:VERA – Free Report) had its price target decreased by JPMorgan Chase & Co. from $77.00 to $71.00 in a report released on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock. Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group initiated […] - 2025-03-05 06:46:57

New York State Common Retirement Fund Boosts Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

New York State Common Retirement Fund raised its stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 19.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 28,822 shares of the company’s stock after acquiring an additional 4,709 shares during the period. New York State Common Retirement Fund’s holdings in Vera Therapeutics were worth […] - 2025-03-03 06:43:01

Back to Listing

Disclaimer